Literature DB >> 9221978

The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies.

W A Sewell1, V M Brennan, M Donaghy, H M Chapel.   

Abstract

High dose intravenous immunoglobulin therapy is becoming the established maintenance treatment for several neurological conditions. Therapeutic immunoglobulin is expensive and its administration is time consuming. Efficacy is variable and must be closely monitored. Here, we show that self infused immunoglobulin at home, combined with daily functional strength diaries to predict dose and dosage intervals, is effective, time saving, and convenient for both patients and medical staff.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9221978      PMCID: PMC2169645          DOI: 10.1136/jnnp.63.1.106

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  4 in total

Review 1.  Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.

Authors:  Mary Lucas; Ken Hugh-Jones; Angela Welby; Siraj Misbah; Peter Spaeth; Helen Chapel
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 2.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

3.  Use of human intravenous immunoglobulin in lower motor neuron syndromes.

Authors:  C M Ellis; S Leary; J Payan; C Shaw; M Hu; M O'Brien; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

4.  Axon loss is an important determinant of weakness in multifocal motor neuropathy.

Authors:  J T H Van Asseldonk; L H Van den Berg; S Kalmijn; R M Van den Berg-Vos; C H Polman; J H J Wokke; H Franssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.